SC
NTLA icon

Saltoro Capital’s Intellia Therapeutics NTLA Stock Holding History

Saltoro Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,000
Closed -$109K – 138
2020
Q4 		$109K Buy
+2,000
New +$72.6K 0.05% 109

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Saltoro Capital's NTLA Position: Q1 2021 in Review

Saltoro Capital sold out of Intellia Therapeutics (NTLA) in Q1 2021, closing a stake of 2,000 shares — an estimated $109K sold.

Saltoro Capital first reported a position in NTLA in Q4 2020 and held it in 1 quarter. The position peaked at $109K in Q4 2020. 260 funds tracked by Wall St. Rank hold NTLA as of Q1 2021.

  • Saltoro Capital reported no remaining Intellia Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Saltoro Capital sold 2,000 Intellia Therapeutics shares in Q1 2021, an estimated $109K.
  • Saltoro Capital first reported a position in Intellia Therapeutics in Q4 2020 and held it in 1 quarter.
  • Saltoro Capital's Intellia Therapeutics position peaked at $109K in Q4 2020.
  • 260 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2021.

Based on Saltoro Capital's 13F filing for Q1 2021, filed 14 May 2021.